495 related articles for article (PubMed ID: 22036653)
21. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Shalash AO; Molokhia AM; Elsayed MM
Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
23. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
Murnane D; Martin GP; Marriott C
J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
[TBL] [Abstract][Full Text] [Related]
24. Entrainment of lactose inhalation powders: a study using laser diffraction.
Watling CP; Elliott JA; Cameron RE
Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
[TBL] [Abstract][Full Text] [Related]
25. Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
Kaialy W; Nokhodchi A
Int J Pharm; 2012 Nov; 437(1-2):57-69. PubMed ID: 22884837
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
Du P; Du J; Smyth HDC
J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
[TBL] [Abstract][Full Text] [Related]
27. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
28. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.
Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
J Control Release; 2004 May; 97(1):19-29. PubMed ID: 15147801
[TBL] [Abstract][Full Text] [Related]
29. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
[TBL] [Abstract][Full Text] [Related]
30. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R
Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553
[TBL] [Abstract][Full Text] [Related]
31. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
Martin GP; Marriott C; Zeng XM
Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
[TBL] [Abstract][Full Text] [Related]
32. Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters.
Thalberg K; Berg E; Fransson M
Int J Pharm; 2012 May; 427(2):224-33. PubMed ID: 22349053
[TBL] [Abstract][Full Text] [Related]
33. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
[TBL] [Abstract][Full Text] [Related]
34. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
35. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
Zhou QT; Morton DA
Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
[TBL] [Abstract][Full Text] [Related]
36. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation.
Giry K; Péan JM; Giraud L; Marsas S; Rolland H; Wüthrich P
Int J Pharm; 2006 Sep; 321(1-2):162-6. PubMed ID: 16797150
[TBL] [Abstract][Full Text] [Related]
37. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
Young PM; Wood O; Ooi J; Traini D
Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
[TBL] [Abstract][Full Text] [Related]
38. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
Ooi J; Gill C; Young PM; Traini D
Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438
[TBL] [Abstract][Full Text] [Related]
39. Functionality testing of inhalation grade lactose.
Steckel H; Markefka P; TeWierik H; Kammelar R
Eur J Pharm Biopharm; 2004 May; 57(3):495-505. PubMed ID: 15093599
[TBL] [Abstract][Full Text] [Related]
40. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
Tong HH; Shekunov BY; York P; Chow AH
J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
